IGM Biosciences, Inc.
IGMS
$1.22
$0.032.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 25.77% | 57.64% | 74.00% | 32.31% | 99.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.77% | 57.64% | 74.00% | 32.31% | 99.25% |
| Cost of Revenue | -27.41% | -10.65% | -3.39% | 8.05% | 19.24% |
| Gross Profit | 27.95% | 11.26% | 4.04% | -7.85% | -18.76% |
| SG&A Expenses | -16.55% | 2.63% | -10.13% | -4.32% | 0.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.35% | -8.05% | -4.74% | 5.50% | 15.17% |
| Operating Income | 25.77% | 8.53% | 5.27% | -5.32% | -14.77% |
| Income Before Tax | 20.32% | 7.68% | 6.08% | -3.46% | -11.14% |
| Income Tax Expenses | -- | -44.50% | 145.92% | 579.31% | -- |
| Earnings from Continuing Operations | 20.54% | 7.74% | 5.95% | -3.68% | -11.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.54% | 7.74% | 5.95% | -3.68% | -11.45% |
| EBIT | 25.77% | 8.53% | 5.27% | -5.32% | -14.77% |
| EBITDA | 26.94% | 9.19% | 6.11% | -4.50% | -14.19% |
| EPS Basic | 32.81% | 26.89% | 30.22% | 16.68% | 10.38% |
| Normalized Basic EPS | 35.97% | 28.24% | 31.57% | 18.39% | 10.19% |
| EPS Diluted | 32.81% | 26.89% | 30.22% | 16.68% | 10.38% |
| Normalized Diluted EPS | 35.97% | 28.24% | 31.57% | 18.39% | 10.19% |
| Average Basic Shares Outstanding | 15.82% | 24.62% | 34.91% | 27.16% | 25.88% |
| Average Diluted Shares Outstanding | 15.82% | 24.62% | 34.91% | 27.16% | 25.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |